This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Infinity Supports Blood Cancer Awareness Month With Launch Of Sparks Of Inspiration, A Campaign To Honor People Affected By Blood Cancer

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) is observing National Blood Cancer Awareness Month, joining patients, healthcare providers and patient organizations in raising public awareness of blood cancers and the need for continued research for novel treatment options. In support of patients and their loved ones, Infinity is launching the Sparks of Inspiration campaign. Throughout the month of September, Infinity encourages the submission of stories along with photos or illustrations to honor friends, family members and loved ones affected by blood cancer. For each submission received, Infinity will make a donation of $10 to the Leukemia & Lymphoma Society (LLS), the world's largest voluntary health organization dedicated to blood cancers.

To learn more about Sparks of Inspiration and submit your tribute, please visit www.infi.com.

“We are grateful for the support from Infinity, which highlights our shared goal of advancing new treatment options for patients affected by blood cancers,” said John Walter, president and CEO of LLS. “Blood Cancer Awareness Month is the right platform to create a sense of urgency about the need to continue investing in lifesaving treatments and cures. As there are no means of prevention of or early detection for most blood cancers, we must focus on cures.”

“Infinity is committed to discovering and developing new medicines for patients with difficult-to-treat conditions, including blood cancers,” commented Pedro Santabarbara, M.D., Ph.D. chief medical officer at Infinity. “Through this campaign, we are honoring the courage and strength of patients with blood cancers and their families. We are pleased to support the Leukemia & Lymphoma Society’s mission of finding cures for blood cancers and improving the quality of life for patients and families.”

Infinity is developing IPI-145, a potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of certain blood cancers.

“Early Phase 1 data of IPI-145 has shown encouraging signs of clinical activity across a broad range of blood cancers. I am excited to be involved in ongoing trials of IPI-145 and look forward to further evaluation of this investigational drug,” said Ian Flinn, M.D., Ph.D., director, hematologic malignancies program, Sarah Cannon Research Institute, and an investigator for these clinical studies of IPI-145. “New targeted agents in development, such as IPI-145, have the potential not only to expand therapeutic options for patients but also to reduce or delay the need for chemotherapy.”

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,079.57 -42.44 -0.25%
S&P 500 1,996.74 -3.38 -0.17%
NASDAQ 4,557.6950 -11.9260 -0.26%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs